| Mapping the human genetic architecture of COVID-19 Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ... Nature 600 (7889), 472-477, 2021 | 716 | 2021 |
| DOCK2 is involved in the host genetics and biology of severe COVID-19 H Namkoong, R Edahiro, T Takano, H Nishihara, Y Shirai, K Sonehara, ... Nature 609 (7928), 754-760, 2022 | 54 | 2022 |
| Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations S Ikemura, H Yasuda, S Matsumoto, M Kamada, J Hamamoto, ... Proceedings of the National Academy of Sciences 116 (20), 10025-10030, 2019 | 51 | 2019 |
| Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations H Hasegawa, H Yasuda, J Hamamoto, K Masuzawa, T Tani, S Nukaga, ... Lung Cancer 127, 146-152, 2019 | 49 | 2019 |
| IGF2 autocrine-mediated IGF1R activation is a clinically relevant mechanism of osimertinib resistance in lung cancer T Manabe, H Yasuda, H Terai, H Kagiwada, J Hamamoto, T Ebisudani, ... Molecular Cancer Research 18 (4), 549-559, 2020 | 39 | 2020 |
| Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm … K Kakimi, H Matsushita, K Masuzawa, T Karasaki, Y Kobayashi, ... Journal for ImmunoTherapy of Cancer 8 (2), 2020 | 27 | 2020 |
| Comparison of detection methods of EGFR T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer K Kobayashi, K Naoki, T Manabe, K Masuzawa, H Hasegawa, H Yasuda, ... OncoTargets and therapy, 3335-3343, 2018 | 24 | 2018 |
| Upregulation of FGF9 in lung adenocarcinoma transdifferentiation to small cell lung cancer K Ishioka, H Yasuda, J Hamamoto, H Terai, K Emoto, TJ Kim, S Hirose, ... Cancer research 81 (14), 3916-3929, 2021 | 18 | 2021 |
| Japan COVID-19 Task Force: a nation-wide consortium to elucidate host genetics of COVID-19 pandemic in Japan H Namkoong, R Edahiro, K Fukunaga, Y Shirai, K Sonehara, H Tanaka, ... Medrxiv, 2021.05. 17.21256513, 2021 | 15 | 2021 |
| The whole blood transcriptional regulation landscape in 465 COVID-19 infected samples from Japan COVID-19 Task Force QS Wang, R Edahiro, H Namkoong, T Hasegawa, Y Shirai, K Sonehara, ... Nature communications 13 (1), 4830, 2022 | 14 | 2022 |
| Comprehensive and long-term surveys of COVID-19 sequelae in Japan, an ambidirectional multicentre cohort study: study protocol K Nakagawara, H Namkoong, H Terai, K Masaki, T Tanosaki, ... BMJ open respiratory research 8 (1), e001015, 2021 | 14 | 2021 |
| SHOC2 is a critical modulator of sensitivity to EGFR–TKIs in non–small cell lung cancer cells H Terai, J Hamamoto, K Emoto, T Masuda, T Manabe, S Kuronuma, ... Molecular Cancer Research 19 (2), 317-328, 2021 | 13 | 2021 |
| Monomer preference of EGFR tyrosine kinase inhibitors influences the synergistic efficacy of combination therapy with cetuximab A Oashi, H Yasuda, K Kobayashi, T Tani, J Hamamoto, K Masuzawa, ... Molecular cancer therapeutics 18 (9), 1593-1601, 2019 | 6 | 2019 |
| Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer T Manabe, TG Bivona The Journal of Clinical Investigation 132 (4), 2022 | 5 | 2022 |
| Functional dissection of the KRAS G12C mutation by comparison among multiple oncogenic driver mutations in a lung cancer cell line model K Kobayashi, H Terai, H Yasuda, J Hamamoto, Y Hayashi, O Takeuchi, ... Biochemical and Biophysical Research Communications 534, 1-7, 2021 | 2 | 2021 |
| Establishment of patient-derived cancer cell lines to elucidate the resistant mechanism of tyrosine kinase inhibitors T Manabe, H Yasuda, H Terai, J Hamamoto, T Ebisudani, K Kobayashi, ... Cancer Research 80 (16_Supplement), 2991-2991, 2020 | | 2020 |
